ArticleViruses2010
An update on canine adenovirus type 2 and its vectors.
Article in Viruses, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Article
- Article
- Calcium Imaging in Vivo: How to Correctly Select and Apply Fiber Optic Photometric Indicators.Organogenesis · 2025Review
- Isolation and characterization of canine adenovirus type 2 (CAV-HN45) and its selective infection of human cervical cancer cells with preliminary oncolytic potential.Frontiers in veterinary science · 2025Article
- Feasibility of Canine Adenovirus Type 2 (CAV2) Based Vector for the Locus Coeruleus Optogenetic Activation in Non-Transgenic Rats: Implications for Functional Studies.Brain sciences · 2022Article
- Altered PVN-to-CA2 hippocampal oxytocin pathway and reduced number of oxytocin-receptor expressing astrocytes in heart failure rats.Journal of neuroendocrinology · 2022Article
- Difference Analysis Between Canine Adenovirus Types 1 And 2.Frontiers in cellular and infection microbiology · 2022Review
- Characterization of Canine Adenovirus Type 2 Virus Infection Pattern in Canine and Human Cell Lines.Advances in virology · 2022Article
- In vitro functional genetic modification of canine adenovirus type 2 genome by CRISPR/Cas9.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- A direct interareal feedback-to-feedforward circuit in primate visual cortex.Nature communications · 2021Article
- Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development.Biomolecules · 2021Review
- Viral tools for neuroscience.Nature reviews. Neuroscience · 2020Review
- Social touch promotes interfemale communication via activation of parvocellular oxytocin neurons.Nature neuroscience · 2020Article
- Cell Bank Origin of MDCK Parental Cells Shapes Adaptation to Serum-Free Suspension Culture and Canine Adenoviral Vector Production.International journal of molecular sciences · 2020Article
- Article
- Novel Genotype Definition and the First Epidemiological Investigation of Canine Adenovirus Type 2 in Dogs in Central China.Frontiers in veterinary science · 2020Article
- Canine Adenovirus 2: A Natural Choice for Brain Circuit Dissection.Frontiers in molecular neuroscience · 2020Review
- Targeting Catecholaminergic Systems in Transgenic Rats With a CAV-2 Vector Harboring a Cre-Dependent DREADD Cassette.Frontiers in molecular neuroscience · 2020Article
- Article
- CAV-2 Vector Development and Gene Transfer in the Central and Peripheral Nervous Systems.Frontiers in molecular neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenovirus vectors have significant potential for long- or short-term gene transfer. Preclinical and clinical studies using human derived adenoviruses (HAd) have demonstrated the feasibility of flexible hybrid vector designs, robust expression and induction of protective immunity. However, clinical use of HAd vectors can, under some conditions, be limited by pre-existing vector immunity. Pre-existing humoral and cellular anti-capsid immunity limits the efficacy and duration of transgene expression and is poorly circumvented by injections of larger doses and immuno-suppressing drugs. This review updates canine adenovirus serotype 2 (CAV-2, also known as CAdV-2) biology and gives an overview of the generation of early region 1 (E1)-deleted to helper-dependent (HD) CAV-2 vectors. We also summarize the essential characteristics concerning their interaction with the anti-HAd memory immune responses in humans, the preferential transduction of neurons, and its high level of retrograde axonal transport in the central and peripheral nervous system. CAV-2 vectors are particularly interesting tools to study the pathophysiology and potential treatment of neurodegenerative diseases, as anti-tumoral and anti-viral vaccines, tracer of synaptic junctions, oncolytic virus and as a platform to generate chimeric vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.